Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
- PMID: 1969613
- DOI: 10.1056/NEJM199004193221605
Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine
Abstract
2-Chlorodeoxyadenosine is a simple purine nucleoside that has previously been shown to be effective in the treatment of low-grade malignant disorders of lymphoid tissue, including chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Because of these encouraging results, we treated 12 patients with another low-grade B-cell neoplasm, hairy-cell leukemia. The patients received 2-chlorodeoxyadenosine (0.1 mg per kilogram of body weight per day) by continuous infusion for seven days. All the patients responded to treatment. Eleven had complete remissions characterized by the normalization of peripheral blood and bone marrow and disappearance of tumor masses. The longest remission has been 3.8 years. None of the patients have relapsed, and the median duration of remission has been 15.5 months. No serious toxic reactions occurred as a result of 2-chlorodeoxyadenosine therapy. These results suggest that 2-chlorodeoxyadenosine may be the most effective therapy available for hairy-cell leukemia. The administration of 2-chlorodeoxyadenosine resulted in a higher rate of complete remission than is observed with interferon alfa, and it required no maintenance therapy. Its toxicity may be lower than that of deoxycoformycin, and the responses were achieved with single courses of treatment.
Similar articles
-
Pentostatin and 2-chlorodeoxyadenosine for hairy-cell leukemia.Med Lett Drugs Ther. 1992 Sep 18;34(879):89-90. Med Lett Drugs Ther. 1992. PMID: 1355592 No abstract available.
-
Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA).Blood. 1992 Feb 15;79(4):882-7. Blood. 1992. PMID: 1346577
-
Clinical trials referral resource. Clinical trials with 2-chlorodeoxyadenosine.Oncology (Williston Park). 1992 May;6(5):95-8. Oncology (Williston Park). 1992. PMID: 1350917 No abstract available.
-
2-Chlorodeoxyadenosine: hairy cell leukemia takes a surprising turn.Blood Cells. 1993;19(3):559-68; discussion 569-72. Blood Cells. 1993. PMID: 8018939 Review.
-
The treatment of hairy cell leukemia: an update.Leukemia. 1992;6 Suppl 2:24-7. Leukemia. 1992. PMID: 1349662 Review.
Cited by
-
Effects of 2-chloroadenine substitution in DNA on restriction endonuclease cleavage reactions.Nucleic Acids Res. 1991 Jun 11;19(11):3143-8. doi: 10.1093/nar/19.11.3143. Nucleic Acids Res. 1991. PMID: 1647525 Free PMC article.
-
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.Int J Hematol. 2004 Oct;80(3):267-77. doi: 10.1532/ijh97.04077. Int J Hematol. 2004. PMID: 15540903 Clinical Trial.
-
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone.Int J Hematol. 2004 May;79(4):311-21. doi: 10.1532/ijh97.04050. Int J Hematol. 2004. PMID: 15218957 Review.
-
BRAF in the cross-hairs.Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26. Expert Rev Hematol. 2019. PMID: 30782032 Free PMC article. Review.
-
The optimal management of hairy cell leukaemia.Drugs. 1995 Jun;49(6):921-31. doi: 10.2165/00003495-199549060-00006. Drugs. 1995. PMID: 7543840 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources